KR101268460B1 - Anti-allergic composition - Google Patents
Anti-allergic composition Download PDFInfo
- Publication number
- KR101268460B1 KR101268460B1 KR1020110025625A KR20110025625A KR101268460B1 KR 101268460 B1 KR101268460 B1 KR 101268460B1 KR 1020110025625 A KR1020110025625 A KR 1020110025625A KR 20110025625 A KR20110025625 A KR 20110025625A KR 101268460 B1 KR101268460 B1 KR 101268460B1
- Authority
- KR
- South Korea
- Prior art keywords
- present
- allergic
- cells
- extract
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000003266 anti-allergic effect Effects 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 22
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 12
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 13
- -1 Packs Substances 0.000 description 11
- 239000006210 lotion Substances 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 7
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920002055 compound 48/80 Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 부작용이 적고 효과적인 천연식물 유래의 알러지 질환 치료를 위하여 희첨(Siegesbeckiae glabrescens) 추출물을 유효성분으로 함유하는 약학적 조성물, 건강기능 식품 및 화장료 조성물을 제공한다.The present invention provides a pharmaceutical composition, health functional food and cosmetic composition containing a extract of Siegesbeckiae glabrescens as an active ingredient for the treatment of allergic diseases derived from natural plants with low side effects and effective.
Description
본 발명은 항알러지용 조성물에 관한 것으로서, 더 상세하게는 천연식물 추출물을 유효성분으로 함유하는 항알러지용 조성물에 관한 것이다.The present invention relates to an anti-allergic composition, and more particularly, to an anti-allergic composition containing a natural plant extract as an active ingredient.
알르레기 또는 알러지(Allergy)란 이물질(항원, Allergen)에 대한 특이하고 변형된 반응을 나타내는 생화학적 현상이며, 이 때 방출된 물질이 증상을 일으키게 되면 알러젠(Allergen)이라 하고 그 결과 생긴 질환을 알러지 질환이라고 한다. 알러지(Allergy)의 발생원인 항원항체반응의 결과로 나타나는 생체의 병적 과정이며, 일반적으로 반응을 일으키는데 필요한 시간 및 보체관여의 유무로부터 제1형 내지 제4형으로 분류되고 있다. Allergy or allergy is a biochemical phenomenon that shows a specific and modified reaction to a foreign substance (antigen, Allergen), and when the released substance causes symptoms, it is called allergen. It is called. It is a pathological process of living organisms resulting from antigen-antibody reactions that are the source of allergy, and is generally classified into type 1 to type 4 from the time required for causing the reaction and the absence of complement involvement.
이 중 제1형은 아나필락틱(anaphylatctic[cytotropic:즉시형]) 형태로 표적기관이 주로 소화장기, 피부 및 폐장으로 일반적인 증상은 위장관 알러지, 담마진, 위축성 피부염, 알러지성 비염 및 기관지성 천식 등이 있다. 제1형의 병리기전은 항원이 비만세포와 호염기구의 표면에 부착되어 있는 IgE 항체에 접촉됨으로써 표적세포를 활성화시켜 히스타민, 세로토닌, 루코트리엔, PAF 등의 화학매체를 분비하여 혈관과 평활근을 수축시킨다고 알려져 있는데 이는 주로 제4형(지연형)과 복합되는 경우가 많다. 즉, 이 아나필라시스와 알레르기 반응은 비만 세포 등에서 일어나는 다양한 변화에 기인된다.Type 1 is anaphylatctic (immediate type). The target organs are mainly digestive organs, skin and lungs. Common symptoms include gastrointestinal allergy, gall bladder, atrophic dermatitis, allergic rhinitis and bronchial asthma. There is this. Pathology of type 1 activates target cells by contacting antigens with IgE antibodies attached to the surface of mast cells and basophils to secrete chemical media such as histamine, serotonin, leukotrienes, and PAF, resulting in blood vessels and smooth muscle. It is known to shrink, which is often combined with type 4 (delayed type). In other words, this anaphylaxis and allergic reaction are due to various changes occurring in mast cells and the like.
최근에 아토피성 피부염과 같은 알레르기성 질환의 증가로 이에 대한 연구가 활발히 진행되어 급진적인 면역학의 발전으로 알레르기성 질환의 구명 및 치료에 많은 진보가 있었음에도 불구하고, 지금까지 개발된 약물 중에 알르레기성 질환을 완치할 수 있는 약물은 없으며 상기 약물을 통한 환자의 증상개선을 기대하고 있으나 부작용이 큰 실정이다.In recent years, research has been actively conducted due to an increase in allergic diseases such as atopic dermatitis, and the development of radical immunology has made a lot of progress in the lifesaving and treatment of allergic diseases. There is no drug that can cure the disease, and the patient is expected to improve symptoms through the drug, but the side effects are large.
본 발명은 상기 문제점을 해결하기 위해 안출된 것으로서, 안전하고 효과적인 천연식물 유래의 알러지 질환 예방 및 치료용 약학적 조성물을 제공하는 것을 목적으로 한다.The present invention has been made to solve the above problems, an object of the present invention to provide a pharmaceutical composition for preventing and treating allergic diseases derived from safe and effective natural plants.
본 발명은 안전하고 효과적인 천연식물 유래의 알러지 질환 예방 및 개선용 건강기능식품을 제공하는 것을 목적으로 한다.The present invention aims to provide a health functional food for preventing and improving allergic diseases derived from safe and effective natural plants.
본 발명은 안전하고 효과적인 천연식물 유래의 알러지성 피부증상 완화 및 개선용 기능성 화장료 조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a functional cosmetic composition for alleviating and improving allergic skin symptoms derived from safe and effective natural plants.
그러나 이러한 과제는 예시적인 것으로, 이에 의해 본 발명의 범위가 한정되는 것은 아니다.However, these problems are exemplary and do not limit the scope of the present invention.
본 발명의 일 관점에 따르면, 희첨(Siegesbeckiae glabrescens) 추출물을 유효성분으로 함유하는 알러지 질환 예방 및 치료용 약학적 조성물이 제공된다.According to an aspect of the present invention, there is provided a pharmaceutical composition for preventing and treating allergic diseases containing Siegesbeckiae glabrescens extract as an active ingredient.
이때, 상기 희첨 추출물은 희첨을 물, C1~C4의 저급알코올 또는 이의 혼합액으로 추출하여 제조거나 이들 추출물을 유기용매로 재차 분획한 분획물이 될 수 있다. 상기 분획물은 특정 유기용매의 단독 분획물일 수 있고, 유기용매의 극성에 따라 순차적으로 분획한 순차분획물 중 어느 하나 이상일 수 있다. 예컨대, 희첨 추출물을 70% 에탄올에 녹인 후, N-헥산, 클로르포름, 에틸 아세테이트, 부탄올 및 물의 순으로 순차분획한 후 해당 유기용매를 증발시켜 남은 잔사 중 효과가 좋은 하나 또는 그 이상의 분획을 사용할 수 있다.At this time, the rare extract may be prepared by extracting the rare water with water, C 1 ~ C 4 lower alcohol or a mixture thereof, or may be a fraction obtained by fractionating these extracts again with an organic solvent. The fraction may be a single fraction of a specific organic solvent, may be any one or more of the sequential fractions sequentially divided according to the polarity of the organic solvent. For example, the rare extract is dissolved in 70% ethanol, and then sequentially fractionated in the order of N-hexane, chloroform, ethyl acetate, butanol and water, and the organic solvent is evaporated to use one or more fractions of the remaining residues. Can be.
상기 알러지 질환은 기관지 천식, 접촉성 알러지, 두드러기, 소양증, 아토피성 피부염, 알러지성 비염, 혈관부종, 음식물 알러지, 약물 알러지 또는 아나필락시스일 수 있으나, 이에 제한되는 것은 아니다.The allergic disease may be, but is not limited to, bronchial asthma, contact allergy, urticaria, pruritus, atopic dermatitis, allergic rhinitis, angioedema, food allergy, drug allergy or anaphylaxis.
본 발명자들은 본 발명의 조성물을 비만세포의 일종인 RBL-2H3 세포에 처리한 결과, 알러지 지표물질인 β-hexosaminidase의 세포외 방출이 억제됨을 확인하였다(도 1 참조). 비만세포(mast cell, RBL-2H3, ATCC No. CRL-2256, 미국)는 면역반응에 의해 활성화되고 알러지의 주요 원인으로 작용하는 히스타민을 분비하는데, 활성화된 비만세포에서 탈과립이 발생하면 히스타민과 함께 β-hexosaminidase를 함께 방출하게 되며 이때 방출되는 β-hexosaminidase는 탈과립의 지표로 사용할 수 있다(Ho, C. et al., Planta Med. 64: 577-578, 1998).The present inventors confirmed that the treatment of the composition of the present invention on RBL-2H3 cells, a kind of mast cells, inhibited the extracellular release of β-hexosaminidase, an allergic indicator (see FIG. 1). Mast cells (mast cell, RBL-2H3, ATCC No. CRL-2256, USA) secrete histamine, which is activated by an immune response and acts as a major cause of allergies. When degranulation occurs in activated mast cells, β-hexosaminidase is released together, and the released β-hexosaminidase can be used as an indicator of degranulation (Ho, C. et al ., Planta Med . 64: 577-578, 1998).
아울러, 본 발명의 발명자들은 상기 희첨 추출물의 효과가 시험관내 조건에서 그치지 않고, 피부에 가려움증 또는 아토피성 피부염 등 알러지 질환이 유발된 동물모델을 대상으로 한 동물실험결과 희첨 추출물이 알러지 질환을 효과적으로 치료할 수 있음을 입증하였다(도 2 및 3 참조). 따라서, 본 발명의 희첨 추출물은 다양한 알러지 질환의 치료용 조성물로 사용될 수 있다.In addition, the inventors of the present invention did not stop the effect of the rare extract in vitro conditions, animal experiments in animal models in which allergic diseases such as itching or atopic dermatitis caused the skin extracts effectively treat allergic diseases Proved possible (see FIGS. 2 and 3). Therefore, the rare extract of the present invention can be used as a composition for treating various allergic diseases.
본 발명의 일실시예 따른 약학적 조성물은 바람직하게는 조성물 총 중량에 대하여 상기 희첨 추출물을 0.1 내지 50 중량% 로 포함한다.The pharmaceutical composition according to one embodiment of the present invention preferably comprises 0.1 to 50% by weight of the rare extract based on the total weight of the composition.
일반적으로 본 발명의 일실시예에 따른 약학적 조성물은 임상 투여시 경구 및 비경구 투여 모두 가능하며, 비경구 투여시 피부도포도 가능하므로, 일반적인 의약품 제제의 형태로 사용될 수 있다.In general, the pharmaceutical composition according to an embodiment of the present invention can be used for oral and parenteral administration during clinical administration, and can also be used in the form of a general pharmaceutical formulation, since it is possible to apply skin during parenteral administration.
본 발명의 일실시예에 따른 경구용 조성물은 제약상 허용되는 담체, 희석제, 충진제, 가용화제 또는 유화제 및 당업계에 널리 공지된 염을 비롯한 불활성 성분을 추가로 포함할 수 있다. 예를 들어, 본 발명의 약학 조성물은 당업계에 널리 공지된 고형 담체를 사용하는 통상적인 방법에 따라 정제형태로 제형화 될 수 있고, 다르게는 젤라틴 또는 셀룰로즈 유도체와 같은 임의의 제약상 허용되는 물질을 사용해 캡슐제 형태로 제조할 수도 있다.Oral compositions according to one embodiment of the present invention may further comprise inert ingredients including pharmaceutically acceptable carriers, diluents, fillers, solubilizers or emulsifiers and salts well known in the art. For example, the pharmaceutical compositions of the present invention may be formulated in tablet form according to conventional methods using solid carriers well known in the art, and alternatively any pharmaceutically acceptable substance such as gelatin or cellulose derivatives It can also be prepared in the form of capsules.
실제 사용에 있어서, 본 발명의 일실시예에 따른 약학적 조성물은 통상적인 제약 조제 기술에 따른 제약 담체와 조합될 수 있다. 담체는, 예를 들어 경구 또는 (정맥내 투여를 비롯한) 비경구 투여에 바람직한 제조에 따라 광범위하게 다양한 형태를 지닐 수 있다.In practical use, the pharmaceutical compositions according to one embodiment of the present invention may be combined with pharmaceutical carriers according to conventional pharmaceutical preparation techniques. The carrier may take a wide variety of forms depending upon the preparation desired, for example, for oral or parenteral administration (including intravenous administration).
본 발명의 일 실시예에 따른 약학적 조성물은 알러지 질환의 치료에 유용하며, 이들 목적을 위해, 통상적인 무독성의 제약상 허용되는 담체, 보조제 및 전달체(vehicle)를 포함하는 투여 단위 제형의 형태로 경구적으로, 또는 (피하 주사, 정맥 주사, 근육내 주사, 흉골내 주사 또는 주입, 경피주입, 비강주입 등) 비경구적으로, 또는 직장내로 투여될 수 있다.Pharmaceutical compositions according to one embodiment of the invention are useful for the treatment of allergic diseases and, for these purposes, in the form of dosage unit dosage forms comprising conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It can be administered orally or parenterally (subcutaneous, intravenous, intramuscular, intrasternal or infusion, transdermal, intranasal, etc.) or rectally.
본 발명의 일실시예에 따른 각각의 경구용 조성물은 제약상 허용되는 담체를 비롯한 불활성 성분을 추가로 포함한다. 본 명세서에서 사용된 "제약상 허용된 담체"란 조성물, 구체적으로 의약 조성물의 활성 물질을 제외한 성분을 지칭하는 용어이다. 제약상 허용되는 담체의 예로는 결합제, 붕해제, 희석제, 충진제, 활택제, 가용화제 또는 유화제 및 염이 포함된다.Each oral composition according to one embodiment of the present invention further comprises an inert ingredient, including a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable carrier" is a term that refers to a composition, specifically an ingredient other than the active substance of the pharmaceutical composition. Examples of pharmaceutically acceptable carriers include binders, disintegrants, diluents, fillers, lubricants, solubilizers or emulsifiers and salts.
본 발명의 다른 관점에 따르면, 희첨 추출물을 유효성분으로 함유하는 알러지 질환 완화 및 개선용 건강기능 식품이 제공된다.According to another aspect of the present invention, there is provided a health functional food for alleviating and improving allergic diseases containing a rare extract as an active ingredient.
본 발명의 일실시예에 따르면 희첨 추출물을 식품에 첨가하여, 알러지 질환 의 예방 및 증상 개선용 건강기능 식품을 제조할 수 있다. 이 경우, 건강기능 식품이라 함은 건강기능식품법 제3조에서 정의하고 있는 바와 같이, 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 가능한 식품을 말하며, 본 발명의 희첨 추출물이 포함될 수 있는 식품의 예로는 각종 캅셀, 정제, 과립제, 드링크제, 차, 음료수, 비타민 복합제 등이 있고, 유효 성분의 양은 그의 사용 목적(예방, 증상 완화, 또는 치료보조적 처치)에 따라 적합하게 결정될 수 있다.According to one embodiment of the present invention, by adding a rare extract to food, it is possible to prepare a functional food for the prevention of symptoms and improvement of symptoms. In this case, the health functional food is manufactured in the form of tablets, capsules, powders, granules, liquids, pills, etc., using raw materials or ingredients having functional properties useful for the human body, as defined in Article 3 of the Health Functional Food Act. It refers to a possible food, and examples of the food which may include the rare extract of the present invention include various capsules, tablets, granules, drinks, tea, beverages, vitamin complexes, and the like, and the amount of the active ingredient is used for its purpose (prevention, symptom relief, Or adjuvant treatment).
본 발명의 건강기능 식품은 아토피성 피부염 등 알러지 질환의 예방 및 증상 개선 목적으로 식품 총 중량에 대하여 희첨 추출물을 0.01 내지 95 중량%, 바람직하게는 1 내지 80 중량%로 포함할 수 있다. 본 발명의 기능성 식품의 제조에는 특별한 제한이 없으며, 통상의 식품제조방법 등 어느 것이라도 그대로 또는 적절히 변형하여 적용할 수 있다.The health functional food of the present invention may include 0.01 to 95% by weight, preferably 1 to 80% by weight of the rare extract based on the total weight of the food for the purpose of preventing and improving symptoms of allergic diseases such as atopic dermatitis. There is no restriction | limiting in particular in manufacture of the functional food of this invention, Any of normal food manufacturing methods, etc. can be applied as it is or modified suitably.
아울러, 본 발명의 다른 관점에 따르면, 희첨 추출물을 유효성분으로 포함하는 알저지성 피부증상 완화 및 개선용 기능성 화장료 조성물이 제공된다.In addition, according to another aspect of the present invention, there is provided a functional cosmetic composition for alleviating and improving allergic skin symptoms comprising a rare extract as an active ingredient.
본 발명의 화장료 조성물에는 상기 유효성분인 희첨 추출물 외에 화장품 제조상 허용되는 각종 보조제, 첨가제 및 담체 등이 첨가될 수 있는데, 이러한 성분으로는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있는데, 이들은 화장품공전에 기재된 것이라면 어느 것이라도 사용가능하다. The cosmetic composition of the present invention may be added various additives, additives, and carriers that are acceptable in the manufacture of cosmetics, in addition to the rare extract as the active ingredient, such components include fats and oils, moisturizers, emollients, surfactants, organic and inorganic Pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation accelerators, coolants, limiting agents, purified water, and the like. Any of those described in the above may be used.
본 발명의 일실시예에 따른 화장료 조성물에 포함되는 희첨 추출물의 배합 비율은 특별히 제한되는 것은 아니나, 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하며, 총중량에 대하여 바람직하게는 0.01-5% 중량 백분율, 보다 바람직하게는 0.01-3% 중량 백분율로 배합된다.The blending ratio of the rare extract contained in the cosmetic composition according to an embodiment of the present invention is not particularly limited, but may be blended within the range not impairing the object and effect of the present invention, and preferably 0.01-to the total weight. 5% by weight, more preferably 0.01-3% by weight.
본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture or the like.
본 발명의 화장료 조성물은 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액 등을 들 수 있다.The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, and includes, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, and the like.
구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다.Specifically, the cosmetic composition of the present invention can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, a moisturizing cream, a hand cream, Packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제,에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.
상기한 바와 같이 이루어진 본 발명의 일 실시예에 따르면, 본 발명은 천연식물 추출물을 유효성분으로 함으로써 부작용이 적고, 모델동물에 투여할 경우 아토피성 피부염, 피부가려움증과 같은 알러지성 질환의 증상이 현저히 개선되기 때문에, 본 발명의 조성물은 알러지 질환를 위한 치료제 뿐만 아니라, 이들 질환의 완화 및 개선을 위한 건강기능 식품 및 알러지성 피부증상의 완화 및 개선을 위한 화장품으로의 이용이 가능하다. 물론 이러한 효과에 의해 본 발명의 범위가 한정되는 것은 아니다.According to one embodiment of the present invention made as described above, the present invention has fewer side effects by using a natural plant extract as an active ingredient, the symptoms of allergic diseases such as atopic dermatitis and skin itching when administered to a model animal remarkably Because of the improvement, the composition of the present invention can be used not only as a therapeutic agent for allergic diseases, but also as a dietary supplement for alleviation and improvement of these diseases and cosmetics for alleviation and improvement of allergic skin symptoms. Of course, the scope of the present invention is not limited by these effects.
도 1은 본 발명의 일실시예에 따른 조성물의 β-hexosaminidase 방출 억제를 통한 항 알러지 효과를 보여주는 그래프도이다.
도 2는 본 발명의 일실시예에 따른 조성물의 가려움증 유발 모델 동물의 가려움증 개선 효과를 보여주는 그래프이다.
도 3은 본 발명의 일실시예에 따른 조성물의 항아토피 효과를 보여주는 사진이다.1 is a graph showing the anti-allergic effect through the β-hexosaminidase release inhibition of the composition according to an embodiment of the present invention.
Figure 2 is a graph showing the itch improvement effect of the itch-induced model animal of the composition according to an embodiment of the present invention.
Figure 3 is a photograph showing the anti-atopic effect of the composition according to an embodiment of the present invention.
이하, 실시예 및 실험예들을 통해 본 발명을 보다 상세히 설명하고자 한다. 그러나 본 발명은 이하에서 개시되는 실시예 및 실험예에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 수 있는 것으로, 이하의 실시예 및 실험예는 본 발명의 개시가 완전하도록 하며, 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. It should be understood, however, that the invention is not limited to the disclosed embodiments and examples, but may be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, It is provided to fully inform the owner of the scope of the invention.
실시예 1: 희첨 추출물의 제조Example 1: Preparation of Rare Extract
희첨(Siegesbeckiae glabrescens)의 뿌리를 제외한 전초(Siegesbeckie Herba.) 300 g을 5 L 플라스크에 넣고 75% 에탄올 3 L을 가하여 4시간 동안 환류시켰다. 고형분을 제거하여 수득한 액상을 여과하고 농축한 후 동결건조 하여 20 g의 추출물을 수득하였다.300 g of starch (Siegesbeckie Herba.) Excluding the roots of Siegesbeckiae glabrescens were placed in a 5 L flask and refluxed for 3 hours by adding 3 L of 75% ethanol. The liquid phase obtained by removing solids was filtered, concentrated and lyophilized to obtain 20 g of extract.
실험예 1: β-hexosaminidase 방출 실험Experimental Example 1 β-hexosaminidase Release Experiment
실험에 사용한 RBL-2H3 세포는 한국세포주은행(KCLB)에서 분양받았으며 세포의 배양을 위하여 10% 열-불활성화 FBS(Gibco BRL, USA)과 1% penicillin 및 streptomycin(Gibco BRL, USA)을 포함한 DMEM(Gibco BRL, USA) 배양액에서 배양하였다. 세포는 37℃, 5% CO2 조건하에서 배양하였고, 세포의 증식에 따른 과밀도 현상을 해소하기 위하여 0.05% trypsin-EDTA 용액(Gibco BRL, USA)을 처리하여 세포를 부유시킨 다음 계대 배양하였다. RBL-2H3 cells used in the experiment were distributed by the Korea Cell Line Bank (KCLB) and DMEM containing 10% heat-inactivated FBS (Gibco BRL, USA) and 1% penicillin and streptomycin (Gibco BRL, USA) for culturing the cells. (Gibco BRL, USA) culture was incubated. Cells were cultured under 37 ° C., 5% CO 2 , and the cells were suspended and passaged after treatment with 0.05% trypsin-EDTA solution (Gibco BRL, USA) in order to eliminate the over-density of cells.
β-hexosaminidase 방출실험은 Dastych의 방법으로 수행하였다(Dastych et al., J. Allergy Clin. Immunol., 103(6): 1108-1114, 1999). 구체적으로 RBL-2H3 세포를 10% FBS를 포함한 DMEM에 현탁시킨 후 24-웰 배양접시에 각 웰당 2×105개의 세포가 들어가도록 한 다음 37℃ 5% CO2 배양기에서 하룻밤 배양하였다. 각 well의 세포들을 세포외 완충액(5 mM KCl, 12.5 mM NaCl, 20 mM HEPES, 1.5 mM MgCl, 1.5 mM CaCl2, 1mM dextros, pH 7.4)로 두 번 세척한 다음 각 웰 당 세포외 완충액과 시료(0, 10, 100, 200 mg/L)를 처리한 후 1 시간동안 반응시켰다. 이후 PMA(50 nM)와 A23187(1 mM)을 사용하여 세포를 37℃ 5% CO2 배양기에서 1 시간 반응시키고 얼음 수조에서 10 분 동안 배양한 후 반응을 종결시켰다. 상등액 20 ㎕를 96 웰 플레이트에 옮기고, 펠렛은 Triton X-100(0.1%) 1㎖를 24 웰 플레이트에 넣고 녹인 후 96 웰 플레이트에 20 ㎕를 첨가하였다. 상등액과 펠렛이 담긴 96 웰 플레이트에 기질 완충액(4-p-Nitrophenyl-N-acetyl-β-D-glucosaminide 1 mM, sodium citrate 0.05 M, pH 4.5) 100 ㎕를 넣고 37℃에서 1 시간 배양시킨 다음 각 웰 당 반응종료 용액(stop solution) 200 ㎕를 첨가하여 반응을 종결시켰다. 그런 다음 Microplate reader(Molecular Devices, USA)를 사용하여 405 nm에서 흡광도를 측정하였다. 시료와 대조군의 흡광도 값으로 다음 식에 의해 총 방출율(%)을 산출하였다.β-hexosaminidase release experiment was performed by Dastych's method (Dastych et al ., J. Allergy Clin. Immunol ., 103 (6): 1108-1114, 1999). Specifically, the RBL-2H3 cells were suspended in DMEM containing 10% FBS, followed by 2 × 10 5 cells per well in a 24-well culture dish, and then cultured overnight in a 37 ° C. 5% CO 2 incubator. Cells in each well were washed twice with extracellular buffer (5 mM KCl, 12.5 mM NaCl, 20 mM HEPES, 1.5 mM MgCl, 1.5 mM CaCl 2 , 1 mM dextros, pH 7.4), followed by extracellular buffer and sample per well. After treatment with (0, 10, 100, 200 mg / L) it was reacted for 1 hour. After using PMA (50 nM) and A23187 (1 mM) the cells were reacted for 1 hour in a 37 ℃ 5% CO 2 incubator and incubated for 10 minutes in an ice bath to terminate the reaction. 20 μl of supernatant was transferred to a 96 well plate, and pellets were dissolved in 1 ml of Triton X-100 (0.1%) in a 24 well plate, and 20 μl was added to the 96 well plate. 100 μl of substrate buffer (4-p-Nitrophenyl-N-acetyl-β-D-glucosaminide 1 mM, sodium citrate 0.05 M, pH 4.5) was added to a 96 well plate containing supernatant and pellets. The reaction was terminated by adding 200 μl of stop solution per well. Then the absorbance was measured at 405 nm using a Microplate reader (Molecular Devices, USA). The total emission rate (%) was calculated by the following equation as the absorbance values of the sample and the control.
총 방출율(%) = [S/(S+P)-Scontrol/(Scontrol + Pcontrol)]×100Total release rate (%) = [S / (S + P) -S control / (S control + P control )] × 100
상기 식에서 S는 상등액의 흡광도, P는 펠렛의 흡광도이고, Scontrol/(Scontrol + Pcontrol)(%)는 자극 없는 상태에서의 자발적인 방출양이다.Where S is the absorbance of the supernatant, P is the absorbance of the pellets, and S control / (S control + P control ) (%) is the spontaneous release in the absence of stimulation.
실험결과, RBL-2H3 cells에서 방출된 β-hexosaminidase의 양은 아무런 처리를 하지 않은 세포에서 9.20±0.60%이었으며, PMA와 A23187로 자극한 세포에서 39.45±1.12%로 아무런 처리를 하지 않은 세포에 비해 유의한(p<0.05) 증가를 나타내었다. 반면 PMA와 A23187 자극 30 분 전 시료를 각각 10, 100, 200 mg/L의 농도로 처리한 세포에서는 총 방출율이 각각 35.33±1.31%, 27.24±1.22, 10.42±1.33%으로 나타나, 시료를 처리하지 않고 PMA와 A23187로 자극한 세포와 비교하여, 모든 농도에서 유의한(p<0.05) 감소를 보였다(도 1).The experimental results showed that the amount of β-hexosaminidase released from RBL-2H3 cells was 9.20 ± 0.60% in untreated cells and 39.45 ± 1.12% in cells stimulated with PMA and A23187, compared with untreated cells. One (p <0.05) increase was shown. On the other hand, in cells treated with 10, 100 and 200 mg /
실험예 2: 동물 실험Experimental Example 2: Animal Experiment
<2-1> 가려움 유발 실험<2-1> Itching Induction Experiment
동물실험은 S.D.계열의 Rat을 이용하여 수행하였다. 구체적으로, 마우스의 목 뒤의 등 부위를 제모하여 노출시킨 후, 가려움을 유발하는 물질인 Compound 48/80(Sigma Chemical Co., USA) 0.5%가 함유된 Krebs-Ringer 완충액(Rothschild, Br. J. Pharmac., 38: 253-262, 1970)을 상기 노출된 피부에 도포하고 1시간 동안 뒷다리로 등을 긁는 횟수를 기록하였다. 24시간 후에 동일 양의 Compound 48/80과 시료를 각각 0, 10, 100 및 200 mg/L 시료를 혼합하여 같은 자리에 도포하여 1시간 동안 긁는 횟수를 기록하였다. 이때, 긁는 정도는 시료 없이 Compound 48/80 만을 도포한 마우스의 긁은 회수를 100으로 하였을 때, 시료와 Compound 48/40의 혼합액을 도포한 후 긁는 횟수로 환산하여 나타내었다.Animal experiments were performed using a rat of SD series. Specifically, after exposing and exposing the back of the mouse's neck, Krebs-Ringer buffer (Rothschild, Br. J ) containing 0.5% of Compound 48/80 (Sigma Chemical Co., USA), a material that causes itching Pharmac . , 38: 253-262, 1970) was applied to the exposed skin and the number of back scratches with the hind legs for 1 hour was recorded. After 24 hours, the same amount of Compound 48/80 and the sample were mixed with 0, 10, 100 and 200 mg / L samples, respectively, and applied to the same place, and the number of scratches was recorded for 1 hour. In this case, the degree of scratching was expressed in terms of the number of scratches after applying the mixed solution of the sample and Compound 48/40 when the number of scratches of the mouse coated with only Compound 48/80 without the sample was 100.
그 결과, 본 발명의 희첨 추출물을 처리한 실험군에서는 농도 의존적으로 등을 긁는 횟수가 현저하게 감소하였음을 알 수 있다(도 2). As a result, it can be seen that in the experimental group treated with the rare extract of the present invention, the number of times of scratching the back was significantly reduced (FIG. 2).
<2-2> 피부 상태 개선 정도<2-2> degree of improvement of skin condition
누드마우스(중앙실험동물, 대한민국)의 등에 UV를 30 분간 조사하여 아토피성 피부염을 유도한 후, 200 mg/L의 희첨추출물 1 ml을 환부에 도포한 후 시간 경과에 따른 치유 효과를 관찰하여 사진촬영하였다(도 3).Induced atopic dermatitis by irradiating UV to the back of nude mice (Central test animal, Korea) for 30 minutes, applying 1 ml of 200 mg / L rare extract to the affected area and observing the healing effect over time. Photographed (Figure 3).
그 결과, 처리후 3일째부터 피부 상태가 현저하게 개선됨을 알 수 있었다.As a result, it was found that the skin condition was remarkably improved from the third day after the treatment.
본 발명은 상기 실시예 및 실험예를 참고로 설명되었으나 이는 예시적인 것에 불과하며, 당해 기술분야에서 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 다른 실시예가 가능하다는 점을 이해할 것이다. 따라서 본 발명의 진정한 기술적 보호 범위는 첨부된 특허청구범위의 기술적 사상에 의하여 정해져야 할 것이다.Although the present invention has been described with reference to the above examples and experimental examples, these are merely exemplary, and it will be understood by those skilled in the art that various modifications and equivalent other embodiments are possible. Therefore, the true technical protection scope of the present invention will be defined by the technical spirit of the appended claims.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110025625A KR101268460B1 (en) | 2011-03-23 | 2011-03-23 | Anti-allergic composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110025625A KR101268460B1 (en) | 2011-03-23 | 2011-03-23 | Anti-allergic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120108086A KR20120108086A (en) | 2012-10-05 |
KR101268460B1 true KR101268460B1 (en) | 2013-06-04 |
Family
ID=47279736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110025625A KR101268460B1 (en) | 2011-03-23 | 2011-03-23 | Anti-allergic composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101268460B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023074951A1 (en) * | 2021-10-28 | 2023-05-04 | 주식회사 세바바이오텍 | Composition for preventing or ameliorating atopic dermatitis |
-
2011
- 2011-03-23 KR KR1020110025625A patent/KR101268460B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
논문(2001.08) * |
논문(2001.08)* |
Also Published As
Publication number | Publication date |
---|---|
KR20120108086A (en) | 2012-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101015702B1 (en) | Compositions comprising Seaweeds extract for improving and alleviating inflammation and irritation of skin | |
TW200423961A (en) | Composition for promoting production of type I collagen and/or elastin | |
JP4634769B2 (en) | Whitening effect improver, method for producing the same, whitening composition using the same, and external preparation for skin containing the same | |
KR101397961B1 (en) | Composition comprising the extract of complex herb an active ingredient for preventing and alleviating allergic or non-allergic skin disease and the use thereof | |
JP6921440B2 (en) | Composition for promoting melanin production containing thistle extract as an active ingredient | |
EP3017822A1 (en) | Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof | |
KR100794360B1 (en) | Cosmetic composition comprising the extract of Crinum asiaticum Linne var. having anti-allergic and anti-inflammatory activity | |
JP4074652B1 (en) | Method for producing catechin derivative | |
JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
KR101863297B1 (en) | Composition for preventing or improving skin wrinkle comprising chlorogenic acid and rutin compound as active ingredient | |
JP2003212786A (en) | Skin care medicament with bamboo extract component as active ingredient | |
TW201116286A (en) | Ceramide production enhancer and moisturizing agent | |
KR101930348B1 (en) | A composition for water tissue containing lava seawater | |
JP2004175734A (en) | Dermopathy inhibitor, dermopathy-improving agent, and skin care preparation for external use containing them | |
KR101268460B1 (en) | Anti-allergic composition | |
KR20090075950A (en) | Therapeutical compositions for obstinate atopic dermatitis | |
KR20090095039A (en) | A composition comprising Rumex japonicus having anti-allergy effect | |
KR101831876B1 (en) | Cosmetic composition for imporving atopic dermatitis comprising isosecotanapartholide | |
JP2007077096A (en) | Antipruritic agent composition | |
KR20090042073A (en) | Compositions of the specific herb extracted complex which has the function of alleviating the irritation and those of cosmetics for allergic skin containing it | |
JP2018522923A (en) | Slimming and skin care composition and method for preparing the same | |
KR101719717B1 (en) | Anti-dandruff composition for treating seborrhoeic dermatitis comprising herbal mixture extract | |
JP7258325B2 (en) | Skin external composition and bath agent composition containing lipolysis accelerator and lipolysis accelerator | |
JP2008169172A (en) | Norcepharadione b derivative having inflammatory cytokine production-inhibiting action, food preparation, cosmetic, antiinflammatory agent comprising the same | |
JP2009235035A (en) | Allergic bronchial asthma inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160405 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170427 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180427 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190326 Year of fee payment: 7 |